Metabolic syndrome

Česká verzia

Authors: M. Souček
Authors place of work: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2009; 55(7-8): 618-621
Category: 134th Internal Medicine Day - 23rd Vanysek's Day Brno 2009 - Vanysek's Lecture

Summary

Metabolic syndrome (MS) has become one of the topical health issues in developed countries. This arises from its increasing prevalence in the population linked to poor lifestyles (stress, overeating, lack of physical activity, smoking) and from its proven significantly negative association with the development of atherosclerosis and thus increased cardiovascular mortality and morbidity. Nevertheless, the approaches to effective MS prevention are known as are the ways of treating and preventing MS sequelae. Prerequisite, however, is an early diagnosis of MS that should become integral to common clinical practice of internal as well as general medicine practitioners.

Key words:
metabolic syndrome – obesity – diabetes mellitus – hypertension – dyslipidemia

Zdroje

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.

2. Alberti KG, Zimmet PZ. Definition, diagnosis and classifications of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.

3. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442–443.

4. Executive summary of the third report of the NCEP expert panel on detection, evalution and treatment of high cholesterol in adults (Adult treatment panel III). JAMA 2001; 285: 2486–2497.

5. Svačina Š a kol. Metabolický syndrom. 3. rozšířené a přepracované vydání. Praha: Triton 2006.

6. Muntner P, He J, Chen J et al. Prevalence of non‑traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14: 686–695.

7. Cífková R, Škodová Z, Lánská V et al. Trends in blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. J Hypertens 2004; 22: 1479–1485.

8. Alexander CM, Landsman PB, Teutssch SM et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP): NCEP – defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210–1214.

9. Mancia G, Parati G, Borghi C et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens 2006; 24: 837–843.

10. Bøg-Hansen E, Lindblad U, Gullberg B et al. Metabolic disorders associated with uncontrolled hypertension. Diabetes Obes Metab 2003; 5: 379–387.

11. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.

12. Malik S, Wong ND, Franklin SS et al. The impact of the metabolic syndrome and diabetes on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–1250.

13. Malik S, Wong ND, Franklin S et al. Cardiovascular disease in U.S. persons with metabolic syndrome, diabetes, and elevated C‑reactive protein. Diabetes Care 2005; 28: 690–693.

14. Zeller M, Steg PG, Ravisy J et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005; 165: 1192–1198.

15. Petrlová B, Rosolová H, Hess Z et al. Depressive disorders and the metabolic syndrome of insulin resistance. Semin Vasc Med 2004; 4: 161–165.

16. Němec P, Goldbergová-Pávková M, Gatterová J et al. Asociace promotorového polymorfismu – 1082 G/A v genu pro interleukin‑10 s produkcí autoprotilátek u revmatoidní artritidy. Čes Revmatol 2008; 16: 104–109.

17. Nemec P, Pavkova-Goldbergova M, Stouračova M et al. Polymorphism in the tumor necrosis factor‑alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin Rheumatol 2008; 27: 59–65.

18. Grundy SM, Hansen B, Smith SC Jr et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551–556.

19. Svačinová H, Nováková M, Placheta Zet al. Benefit of combined cardiac rehabilitation on exercise capacity and cardiovascular parameters in patients with type 2 diabetes. Tohoku J Exp Med 2008; 215: 103–111.

20. Svačinová H. Pohybová léčba u pa-cientů s metabolickým syndromem. Vnitř Lék 2007; 53: 540–544.

21. Dahlöf B, Sever PS, Poulter NR et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.

22. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.